You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Cognitive Residential Heat Pump Fault Detection and Diagnostic Datalogger

    SBC: MANAGEMENT SCIENCES INC            Topic: 9010173R

    Millions of heat pumps are used to heat and cool homes and buildings year round. Continuous operation means that components wear out at a greater rate. As a result, maintenance of residential heat pumps is a major cost driver. Current methods focus on reduced use through control settings. Typically, demand has wide swings throughout the day and people are unable to customize controls. Inevitably, ...

    SBIR Phase I 2014 Department of CommerceNational Institute of Standards and Technology
  2. Local Lymph Node Assay with IL-18 Endpoints

    SBC: MB RESEARCH LABORATORIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The current industry standard for predicting contact dermal sensitization is the murine Local Lymph Node Assay (LLNA). A significant limitation of the LLNA is the frequency of false positives, as well as the occurrenceof false negatives. This limitation occurs as a result of the LLNA inability to always correctly distinguish between substances that are strongly ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Ubiquitin pathway inhibitors for treatment of asthma

    SBC: Progenra, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Asthma is a chronic disease with considerable morbidity and no cures. Symptomatic treatment is efficacious but produces significant adverse effects. Thus, improved, targeted therapies for asthma are needed. Asthma develops when T cells (CD4+) differentiate to effector T cells, which secrete cytokines that assist in the recruitment and proliferation of various i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenz

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite improvements in vaccine design, manufacture, and distribution, influenza A infection remains a significant public health concern. The February 2013 CDC Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness reported overall vaccine effectiveness of 56% and 67% against influenza A and B infections, respectively, with much reduced effect ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Peptide inhibitors of coronavirus entry

    SBC: Autoimmune Technologies, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad long-term objectives of the proposed work are to develop effective medical countermeasures to be used for the treatment of viral infectious disease caused by exposure to human coronaviruses. The work will focus on the discovery and development of peptide-based therapeutics for the treatment of persons infected with the newly identified Middle Eastern ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A New Generation of Botulinum Toxin Vaccines

    SBC: INVENTOX INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum toxin is one of the six categories of pathogens that have been designated as Category A Select Agents by the Centers for Disease Control. The toxin, which is generally acknowledged to be the most potent biological poison known, enters the body and acts on peripheral cholinergic nerve endings to cause paralysis of transmission. In seriously poisoned pa ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Single Antiviral to Treat Multiple Opportunistic Infections

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Transplant patients are quite susceptible to opportunistic viral infection resulting from immune suppression necessary for maintenance of their graft. In the case of renal transplant, 17,604 patients in 2011, a new graft means being taken off dialysis, improving quality of life and saving U.S. healthcare nearly 1 B annually. Therefore it is essential that the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Novel bispecific T cell engaging antibodies for treatment of Lyme disease

    SBC: ABZYME THERAPEUTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Lyme disease (LD) is the most commonly reported tick-borne illness in the United States. According to the recent Center for Disease Control and Prevention report, approximately 300,000 Lyme cases are diagnosed each year. If left untreated, the infection spreads to joints, the heart and the nervous system. In most cases, infections and associated symptoms are el ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. An antimicrobial-eluting bioresorbable bone filler for orthopaedic application

    SBC: CarMell Therapeutics Corporation            Topic: NIAMS

    DESCRIPTION (provided by applicant): The long-term goal of Carmell Therapeutics for this proposal is to develop a blood plasma-based biomaterial bone filler product that will elute antimicrobials to inhibit infection. Bacterial contamination is present perioperatively in 48-68% o all open wounds and 100% of severe open injuries. Per year in the U.S. ~ 123,000 open tibia fractures are contaminated, ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Coincident light/ultrasound therapy to treat acne vulgaris and atopic dermatitis

    SBC: SONIC TECH, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Sonic Tech Inc. is developing a unique energy-based therapy called CLENS (Coincident Light Energy and Non-focused ultraSound). Using two well-established clinical energy sources in a novel way, the technology is intended to treat dermal diseases caused by biofilms, a bacterially generated slime layer. Biofilms shield bacteria from attack by both antibiotics an ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government